Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition.

RNA secondary structure is a key determinant of RNA biology and therapeutic efficacy. In this eBlog, we review how RNA structure affects the development of RNA vaccines, siRNAs, and ASOs.

SAN DIEGO, September 3, 2024 — Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in developing precision solutions for RNA-based and RNA-targeting therapeutics, today announced the launch of its eSENSE dsRNA™ assay. eSENSE dsRNA is a next-generation sequencing method for the robust quantification, localization, and optimization of double-stranded RNA (dsRNA) contaminants in RNA-based vaccines and therapeutics. “By […]

dsRNA is an IVT by-product that can limit the efficacy of RNA-based vaccines and therapeutics. In this eBlog, we review how to detect and reduce dsRNA.

Eclipsebio is proud to announce their sponsorship of RNA UK 2024, the premier event for bringing experts in RNA biology together to discuss the latest RNA discoveries.